Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 12Active not recruiting 9Not yet recruiting 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

pembrolizumab 13Nivolumab 6Cyclophosphamide 6Carboplatin 6Specimen Handling 5Pemetrexed 5Paclitaxel 5Docetaxel 5Cisplatin 5Cetuximab 5Bevacizumab 5fludarabine phosphate 4fludarabine 4atezolizumab 4tislelizumab 3durvalumab 3Standard of Care 3Practice Guidelines as Topic 3Methods 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Gemcitabine 3Educational Status 3Early Intervention, Educational 3130-nm albumin-bound paclitaxel 3venetoclax 2tremelimumab 2temsirolimus 2niraparib 2ixazomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × liposomal doxorubicin × 30 days × Clear all
NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Novartis

Phase 3 Terminated
358 enrolled 19 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡